• Suche
1 Aktie gratis
Trading
Suche
1 Aktie gratis
Wertpapierhandel für 0 Euro
Trading
zero-Trading
ETF-Sparplan

Adaptive Biotechnologies Aktie

7,00EUR
+0,07EUR
+1,01%
21:45:22
STU
7,57USD
+0,04USD
+0,53%
22:00:00
NDB

WKN: A2PLR5 / ISIN: US00650F1093 / Symbol: ADPT

  Kaufen  
Verkaufen
oder
mehr Daten anzeigen
Werbung

Times and Sales (XETRA)

ZeitKursUmsatz
Zur Zeit stehen keine Daten zur Verfügung
weiter
Werbung

News zu Adaptive Biotechnologies Corporation Registered Shs

05.05.22Adaptive Biotechnologies präsentierte Bilanzzahlen zum jüngsten Jahresviertel
03.05.22Ausblick: Adaptive Biotechnologies präsentiert Quartalsergebnisse
19.04.22Erste Schätzungen: Adaptive Biotechnologies öffnet die Bücher zum abgelaufenen Quartal
16.02.22Adaptive Biotechnologies: Was beim Unternehmen in den jüngsten Büchern steht
31.01.22Erste Schätzungen: Adaptive Biotechnologies verkündet Quartalsergebnis zum jüngsten Jahresviertel

Analysen zu Adaptive Biotechnologies Corporation Registered Shs

n/a

Aktuelle News zu

23:36 UhrAlkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors
23:35 UhrSelenskyj beklagt Zögerlichkeit bei Sanktionen gegen Russland
23:35 UhrItalian court dismisses case against Tenaris’s Chairman and Chief Executive Officer and two other Board members over allegedly improper payments
23:35 UhrCarbon Market: Results of May 18th Auction held between Québec and California
23:32 UhrCantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor
23:30 UhrRestaurant Brands International Inc. to Participate in RBC Capital Markets 2022 Global Consumer & Retail Conference
23:30 UhrRestaurant Brands International Inc. to Participate in RBC Capital Markets 2022 Global Consumer & Retail Conference
23:29 UhrDXC Technology, Lloyd's und IUA verlängern Vertrag zur Unterstützung der Transformation des Londoner Versicherungsmarktes
23:29 UhrAurora Cannabis Inc. Announces US$125 Million Bought Deal Financing
23:29 UhrRutschen die US-Börsen in einen langanhaltenden Bärenmarkt?
23:28 UhrSummit Midstream Partners, LP Announces Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
23:27 Uhr100% AND MLB ALL-STAR FERNANDO TATIS, JR. DEBUT 2022 LIMITED-EDITION SPORT PERFORMANCE EYEWEAR COLLECTION
23:25 UhrNew 'rebel' elopement planner kicks tradition to the curb with all-inclusive service for alternative couples
23:23 UhrUSA weisen Russlands Forderung nach Aufhebung von Sanktionen zurück
23:23 UhrCarisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting
23:16 UhrBGL Announces the Sale of ROCA ACERO S.A. de C.V.
23:16 UhrDouglas Emmett Declares Quarterly Cash Dividend
23:15 UhrVenzee Technologies Updates Schedule Details for Webcast and First Quarter 2022 Financial Release
23:15 UhrCaris Life Sciences to Showcase Extensive Research with Leading Cancer Centers Reflecting Its Commitment to Improving Outcomes for Patients at ASCO 2022
23:15 UhrVenzee Technologies Updates Schedule Details for Webcast and First Quarter 2022 Financial Release
23:12 UhrNASDAQ, S&P 500 & Co: Tesla-Aktie, Apple-Aktie, Amazon-Aktie, Microsoft-Aktie & Co im Fokus: Das sind die Bilanzen der Tech-Riesen in der aktuellen Saison
23:10 UhrProtagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
23:10 UhrFür Tesla: Musk sucht auf Twitter nach neuer Rechtsabteilung - und erntet Kritik
23:08 UhrKaryopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
23:07 UhrNASA Supports Small Business Research to Power Future Exploration
23:05 UhrSILVERCORP REPORTS ADJUSTED EARNINGS OF $52.4 MILLION, $0.30 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $107.4 MILLION FOR FISCAL 2022
23:05 UhrNew Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access
23:05 UhrElevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022
23:05 UhrSILVERCORP REPORTS ADJUSTED EARNINGS OF $52.4 MILLION, $0.30 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $107.4 MILLION FOR FISCAL 2022
23:05 UhrPuma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
23:01 UhrElectra Makes Steady Progress in Q1 2022 Towards Commissioning its Cobalt Refinery
23:01 UhrFDA Flexibilities, Collaboration to Yield Millions of Bottles of Specialized Medical Infant Formula in Coming Months to Increase U.S. Supply
23:01 UhrMILE MARKER INDUSTRIES ANNOUNCES MANAGEMENT CHANGES
23:01 UhrI-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
23:01 UhrGracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting
23:01 UhrElectra Makes Steady Progress in Q1 2022 Towards Commissioning its Cobalt Refinery
23:01 UhrXencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
23:01 UhrSpectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
23:00 UhrSQI Diagnostics Reports Second Quarter 2022 Results
23:00 UhrTriNet to Participate at the Stifel 2022 Cross Sector Insight Conference
23:00 UhrCTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual Meeting
23:00 UhrNext-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers
23:00 UhrMARTIN UNIVERSITY ANNOUNCES DATA SECURITY INCIDENT
23:00 UhrLeap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting
23:00 UhrBelong.Life Real-World Patient Research Analyzes the Impact of COVID-19 on Cancer Diagnosis in ASCO 2022 Abstract
23:00 UhrZovio Advances Turnaround Plan and Strengthens Financial Position
23:00 UhrNEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022
23:00 UhrInvestigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
23:00 UhrLilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
23:00 UhrSQI Diagnostics Reports Second Quarter 2022 Results
finanzen.net zero

Aktien kaufen ohne Kosten

finanzen.net zero
Aktien, ETFs, Derivate, Kryptos und mehr jetzt für 0 Euro pro Trade handeln!
JETZT INFORMIEREN
Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
JETZT MEHR ERFAHREN
Zur klassischen Ansicht wechseln
Hilfe & Kontakt
Impressum
Werben
Presse
mehr anzeigen